Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors.Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in the Russian Federation (SGN-35...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-01-01
|
| Series: | Onkogematologiâ |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/320 |